Critical Therapeutics launches Phase I clinical trial of anti-inflammatory compound

Cambridge, Mass., June 17, 2003 Critical Therapeutics, Inc. (CTI), a private biopharmaceutical company developing novel therapeutic products for critical care medicine, today announced the initiation of a dose-escalating Phase I clinical trial of its ethyl pyruvate compound, CTI-01.

The primary aim of the trial is to determine the safety and tolerability of the anti-inflammatory compound over a range of doses in healthy volunteer subjects. The trial will be conducted at the Clinical Pharmacology Research Unit at Parexel, Northwick Park Hospital in the United Kingdom. CTI's Phase I trial marks the first time the compound will be administered intravenously to humans.

"This study encompasses the achievement of several milestones," said CTI President and CEO Paul Rubin, M.D. "It marks CTI's first clinical trial in the Company's brief history and is especially notable because CTI-01 was discovered by Mitch Fink M.D., one of the company's founders. The speed and efficiency which with which we have advanced CTI-01 into human trials reflects the dedication and initiative of our entire team."

CTI-01 is a cytoprotective compound that reduces vascular and organ damage following severe insults to the body such as surgical and non-surgical trauma, pancreatitis or overwhelming infection. The small molecule has demonstrated potent anti-inflammatory and tissue protection activity in multiple animal treatment models of disease including pancreatitis, vascular reperfusion injury, hepatitis and endotoxemia. CTI-01 has the potential to prevent and reverse complications in patients undergoing serious operations or multi-organ failure associated with life- threatening acute conditions including shock, myocardial infarction, acute pancreatitis, burns, stroke or acute drug allergies.

Approximately $180 billion is spent each year to treat patients with these life threatening conditions, according to a study conducted by researchers at the Universit

Contact: Scott Solomon
Sharon Merrill Associates, Inc.

Page: 1 2

Related biology news :

1. Critically endangered monkey species plummets more than 50 percent since 1994
2. Save The Tiger Fund announces alliance with the Critical Ecosystem Partnership Fund
3. Critical Therapeutics announces issuance of US patent for novel anti-inflammatory technology
4. Medimmune and Critical Therapeutics to co-develop treatments for severe inflammatory diseases
5. Critical early-defense trigger in plants found
6. Critical therapeutics is awarded U.S. patents for methods to diagnose and treat inflammatory disease
7. Researchers, Regulators, Industry, Consumer Advocates Gather to Discuss Critical Issues Facing the Pharmaceutical Industry
8. Study Furthers Understanding Of Critical Alzheimers Disease Gene
9. Gene Once Thought To Program Ovarian Development Instead Found To Be Critical For Production Of Sperm
10. UF Researchers: Gene Therapy Replaces Critical Protein In Animal Model Of Often-Fatal Lung-Liver Disease
11. Columbia Researchers Synthesize Compound With Possible Link To MacularDegeneration; Work Is Critical To Pinpointing Causes Of Disease, Scientists Say

Post Your Comments:

(Date:3/27/2021)... ... March 25, 2021 , ... Phlexglobal announced ... Planet Group, has selected Phlexglobal and its innovative regulatory SaaS software, PhlexSubmission, as ... a comprehensive review of five regulatory software companies, with the review team including ...
(Date:3/27/2021)... ... 25, 2021 , ... The 2021 Virtual Conference on Clinical Trial Supply-Europe ... More and more, clinical trial supply conferences are featuring speakers and forums that ... Asymmetrex’s founder and CEO, James L. Sherley, M.D., Ph.D., presented a talk ...
(Date:3/23/2021)... ... March 23, 2021 , ... G-CON Manufacturing (G-CON), the ... by Matica Biotechnology (Matica Bio), a contract development and manufacturing organization (CDMO) specializing ... the cleanroom build out for its new GMP production facility in College Station, ...
Breaking Biology News(10 mins):
(Date:3/27/2021)... ... March 24, 2021 , ... ... Life Sciences and Healthcare firms of all sizes, adds depth to its team ... specialist. Pardillo, who earned his doctorate in computational chemistry from Florida International University ...
(Date:3/27/2021)... ... March 24, 2021 , ... ABI Wellness, ... and reporting approach designed under CEO Mark Watson, today announced a webinar dedicated ... featuring guest speakers Dr. Cameron Clark, Neuropsychologist and Founder of Sharp Thinking, and ...
(Date:3/27/2021)... ... ... The Xtalks editorial team is pleased to announce the launch of the ... joined by editorial team members Ayesha Rashid, Sydney Perelmutter and Mira Nabulsi to discuss ... including insights from industry experts. , The Xtalks Life Science podcast will feature ...
(Date:3/23/2021)... Conn. (PRWEB) , ... March 23, 2021 , ... ... develops solutions for characterizing microbiome populations down to the strain level, recently unveiled ... applications. , Not all microbes are created equal: some are easy to ...
Breaking Biology Technology:
Cached News: